Allarity Therapeutics, Inc. ( ALLR) Stock. Should you Buy or Sell? $ 1.17
-0.13 (-12.50 %)
Allarity Therapeutics, Inc. Analysis
Updated on 10-09-2022
|52 Week Range
||$1.01 - $18.2
Allarity Therapeutics, Inc. opened the day at $1.17 which is -12.50 % on yesterday's close.
Allarity Therapeutics, Inc. has a 52 week high of $18.2 and 52 week low of $1.01, which is a difference of $17.19.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $11.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Allarity Therapeutics, Inc. for $11.63 M, it would take 15 years to get your money back. Allarity Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
1 D | All
Allarity Therapeutics, Inc. Stock Forecast - Is Allarity Therapeutics, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|ROE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin
Valuing Allarity Therapeutics, Inc.
|Price Book Value Ratio
||Price To Book Ratio
|Price To Sales Ratio
||Price Earnings Ratio
How liquid is Allarity Therapeutics, Inc.
||Debt Equity Ratio
|Long Term Debt To Capitalization
||Total Debt To Capitalization
Latest news about Allarity Therapeutics, Inc.
Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR
Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Date : 27/05/2022
About Allarity Therapeutics, Inc.
Sector : Healthcare
Industry : Biotechnology
Website : https://www.allarity.com
Exchange : NASDAQ Global Market
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.